Sixth MEG System Sale Pushes Compumedics’ Contracted Orders to $30 Million

Compumedics Expands MEG Footprint in China

Compumedics Limited (ASX, CMP) has announced a significant new sales order worth approximately $4.2 million for its Orion LifeSpan™ magnetoencephalography (MEG) system from Shandong Normal University in China. This marks the company’s sixth MEG system sale, bringing total contracted MEG orders to around $30 million. The deal was secured through Beijing Fistar, Compumedics’ trusted distributor in China, underscoring the company’s growing presence in this strategically important market.

The MEG system, a cutting-edge neuro-imaging platform, is expected to contribute to Compumedics’ revenue in fiscal year 2027, following established production and site-readiness schedules. The contract includes the dual-helmet Orion LifeSpan™ system designed for both adult and paediatric use, integrated with the company’s proprietary CURRY neuro-imaging software and related peripherals.

Leadership in a Complex, High-Value Market

MEG technology is one of the most technically demanding and high-value segments within brain imaging, with few credible suppliers globally. Compumedics’ latest order further validates its technological leadership and commercial execution in this niche but growing field. The Orion LifeSpan™ platform’s advanced sensors and unique dual-helmet design set it apart, offering unmatched precision and operational efficiency, including a helium-free cooling system that supports continuous 24/7 operation.

China’s demand for advanced neuroscience research infrastructure continues to accelerate, positioning it as a key growth market for Compumedics. The company benefits from an expanding installed base and a deepening pipeline of MEG opportunities not only in China but also across North America and Europe. This momentum complements Compumedics’ broader portfolio, which includes sleep, neuro, and software-as-a-service platforms.

Investor Outlook and Strategic Implications

With six MEG systems now contracted, Compumedics’ order book provides clear near- and medium-term revenue visibility, supporting a pathway to sustainable growth. The company anticipates that revenue recognition will align with production, delivery, and installation milestones, reflecting the complex nature of these high-value contracts.

Executive Chairman Dr David Burton highlighted the strategic importance of the MEG business, noting its ability to deliver large contract values and long-term revenue visibility. The recent order from Shandong Normal University not only reinforces Compumedics’ position as a global neuro-imaging leader but also signals confidence from leading research institutions in its technology.

Global Neuro-Imaging Business Director Gordon Haid echoed this sentiment, pointing to the growing maturity of the Orion LifeSpan™ platform and the strong demand pipeline, particularly in China. As Compumedics continues to scale its MEG business, the company appears well positioned to capitalise on the expanding global market for advanced brain imaging solutions.